Clinical trial

A Study to Learn About the Effect of Study Medicine Called PF-08653944 on How Quickly the Stomach Empties Its Content in Healthy Adults With Overweight or Obesity

Active, not recruiting · Phase 1 · 1 countries · Registry ID NCT07508241

Active, not recruitingPhase 1Interventional

What this study is about

This study looks at how a study medicine called PF-08653944 affects how quickly the stomach empties food after eating. It is being done in adults who are overweight or have obesity. Participants will receive the study medicine for a short period, and doctors will measure how the medicine moves through the stomach and monitor safety. The goal is to better understand how this medicine works in the body and to check for any side effects. The information from this study may help researchers plan future studies of this medicine.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to Not listed

SexAll

Healthy volunteersAccepted

ConditionObesity, Overweight and/or Obesity, Overweight, Drug Interaction

Full registry criteria

Inclusion Criteria: * Adults ≥18 years at screening, male or female, generally healthy as determined by medical history, physical examination, laboratory tests, and ECG. * Body mass index (BMI) 27-45 kg/m² and body weight \>50 kg (110 lb). * Participants with overweight or obesity Exclusion Criteria: * History or presence of clinically significant medical conditions, including but not limited to: --Cardiovascular, hepatic, renal, pulmonary, endocrine, hematologic, neurologic, gastrointestinal (including pancreatitis or gallbladder disease), or significant psychiatric disorders. * Any form of diabetes, HbA1c ≥6.5%, or fasting plasma glucose ≥126 mg/dL. * Prior exposure to a GLP-1 receptor agonist within 90 days before first dose, or prior participation in a study with PF-08653944.

Treatments and study arms

PF-08653944

Drug

Subcutaneous Injection

Acetaminophen

Drug

Oral suspension

Primary outcomes

Acetaminophen Pharmacokinetic (PK) Parameters: Maximum observed plasma concentration (Cmax)Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention.

To assess the effect of multiple SC doses of PF-08653944 on the plasma PK profile of acetaminophen, a marker for gastric emptying, in healthy adult participants with overweight or obesity.

Acetaminophen PK parameters: Area under the plasma concentration (AUC)Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention.

To assess the effect of multiple SC doses of PF-08653944 on the plasma PK profile of acetaminophen, a marker for gastric emptying, in healthy adult participants with overweight or obesity.

Acetaminophen PK parameters: Time to Maximum concentration (Tmax)Day 1 pre-dose through approximately 11 Weeks after last dose of study intervention.

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Pfizer Clinical Research Unit - New Haven🇺🇸 New Haven, Connecticut, United States

Open map